Y. Tian

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.

L. Maier, C. Tschöpe, M. Ciccarelli, 2020, Cardiovascular research.